Spinal Muscular Atrophy (SMA) - Novartis
Spinal Muscular Atrophy (SMA) SMA is a rare and devastating genetic disease caused by a lack of a functional survival motor neuron 1 (SMN1) gene, resulting in the rapid and irreversible loss of motor …
Novartis Expands Spinal Muscular Atrophy Gene ... - BioSpace
Nov 25, 2025 · The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access to patients two years and older in what one Stanford …
FDA Approves Gene Therapy Onasemnogene Abeparvovec for ...
Nov 25, 2025 · Novartis receives FDA approval for Itvisma, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA). News release. …
Novartis secures approval from FDA for Itvisma to treat SMA
Nov 25, 2025 · Novartis has received approval from the US Food and Drug Administration (FDA) for the Itvisma (onasemnogene abeparvovec-brve) gene replacement therapy to treat spinal muscular …
Muscular Dystrophy Association Calls FDA Approval of Novartis ...
Nov 24, 2025 · Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy …
Novartis Drug for Spinal Muscular Atrophy Gets FDA Approval
Nov 24, 2025 · Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration. Itvisma, or onasemnogene abeparvovec …
Novartis peels back Zolgensma IT data in older SMA patients
Mar 19, 2025 · A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the treatment of older patients with spinal muscular atrophy …
Novartis Receives FDA Approval for Itvisma®, the only gene ...
5 days ago · At Novartis, we’re doubling down on our commitment to neurology, expanding our legacy of innovation in spinal muscular atrophy (SMA) and multiple sclerosis (MS) to work in …
FDA approves Itvisma in spinal muscular atrophy for patients ...
4 days ago · The FDA has approved an adeno-associated virus 9 gene replacement therapy to treat individuals aged 2 years and older with spinal muscular atrophy and a confirmed mutation of the …
FDA Approves Novartis Gene Therapy Itvisma for Rare Muscle ...
Nov 25, 2025 · Novartis Gene Therapy: The FDA has granted approval for Novartis' gene therapy Itvisma, designed for spinal muscular atrophy in patients two years and older, marking a significant …